Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reliable cognitive changes the first year following guideline-based treatment of isocitrate dehydrogenase mutated gliomas: A longitudinal multicenter study.

Neuro-oncology - 1 Mar 2026

Rydén Isabelle, Latini Francesco, Alberius Munkhammar Åsa, Hellström Per, Neimantaite Alice, Lycett Andrew, Harba Dima, Carstam Louise, Blomstrand Malin, Zetterling Maria, Smits Anja, Jakola Asgeir S

Abstract excerpt

BACKGROUND: Management of isocitrate dehydrogenase (IDH) mutated gliomas is multidisciplinary and current guidelines support early multimodal treatment. The effects of this treatment approach on cognition are less studied. We aimed to study changes in cognitive functioning the first year following treatment in these patients and explore predictors of cognitive deterioration. METHODS: Patients with a first-time...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cognition
Share to Cognitive Dysfunction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Longitudinal Studies

Share to Neuropsychological Tests

Share to Practice Guidelines as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 41206933
DOI: 10.1093/neuonc/noaf263
PMCID: PMC13070499

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reliable cognitive changes the first year following guideline-based treatment of isocitrate dehydrogenase mutated gliomas: A longitudinal multicenter study.PMID 41206933Read ↗

Cognitive functioning is prognostic in patients with IDH1-wild type and MGMT-unmethylated high-grade gliomas.Semantic proximity Read ↗

Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review.Semantic proximity Read ↗

MGMT promoter gene methylation and neurological scale improvement in glioma: a cohort studySemantic proximity Read ↗

Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.Semantic proximity Read ↗

Cognitive issues in patients with IDH mutant gliomas: from neuroscience to clinical neuropsychology.Semantic proximity Read ↗

Molecular determinants of neurocognitive deficits in glioma: based on 2021 WHO classificationSemantic proximity Read ↗

Cognitive phenotypes: Unraveling the heterogeneity in cognitive dysfunction among patients with primary brain tumors receiving radiotherapy.Semantic proximity Read ↗

Molecular Determinants of Neurocognitive Deficits in Glioma: Based on 2021 WHO Classification.Semantic proximity Read ↗

Cognitive functioning in a cohort of high-grade glioma patients.Semantic proximity Read ↗

Neuropsychological Outcomes After Awake Resections of Right Frontal IDH-Mutated Glioma: Insights From a Consecutive Series of 20 Cases.Semantic proximity Read ↗

Long-term autonomy, professional activities, cognition, and overall survival after awake functional-based surgery in patients with IDH-mutant grade 2 gliomas: a retrospective cohort studySemantic proximity Read ↗

Neurocognitive and Resting-State Functional Magnetic Resonance Imaging Changes in Patients With Diffuse Gliomas After Chemoradiation Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.